Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Cerebral folate deficiency is a rare neurological disorder characterized by a decrease in CSF folate levels, leading to developmental regression, seizures, movement disorders, and other neurological ...

NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, Inc. (“Bluejay” ...

AnaptysBio (NASDAQ:ANAB) is preparing to separate its business into two entities, with CEO Daniel Faga telling Barclays Senior Biotech Analyst Gena Wang that the company expects to create a new ...

Between tech giants and coal companies, the new rules of blue-chip investing might look different to the past.

The Food and Drug Administration is approving a generic drug for a very rare genetic disorder, but not for autism.

RM100 today! T&Cs apply. Mr. Bobby Sheng, Chairman of Bora Group, stated, "2025 represented a pivotal year for Bora Group.

The FDA is approving a generic drug for a very rare genetic disorder, but not for autism. On Tuesday, the U.S. agency said the drug helps children and adults who ...

Futures rose amid a reported plan for a record release of crude oil reserves. Oracle jumped on earnings late.

Zymeworks Inc., a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, reported financial results ...